Investigational drug · Phase 2
E7090
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cholangiocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "E7090"
First trial start
2020
Jan 22, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "E7090", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cholangiocarcinoma
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "E7090" as an intervention, largest first.
- NCCH2006/MK010 Trial (FORTUNE Trial)Recruiting
National Cancer Center, JapanGovernment (non-federal)
NCT04962867 · 75 participants (planned) · Start Jun 15, 2021 · Primary completion Mar 31, 2028
Drug: E7090 · For: Advanced or Recurrent Solid Tumors; FGFR Gene Alterations
Sites: Chuo-ku, Tokyo, Japan; Yokohama, Japan; Aoba-ku, Sendai, Miyagi, Japan · 7 sites in all
Eisai Co., Ltd.Eisai
NCT04238715 · 63 participants · Start Jan 22, 2020 · Primary completion Nov 3, 2025
Drug: E7090 · For: Cholangiocarcinoma
Sites: Bengbu, China; Hefei, China; Beijing, China · 56 sites in all
Eisai Co., Ltd.Eisai
NCT04572295 · 51 participants · Start Oct 9, 2020 · Primary completion Jun 18, 2026
Drug: E7090; Fulvestrant and 1 more · For: Breast Neoplasms
Sites: Nagoya, Japan; Kashiwa, Japan; Matsuyama, Japan · 11 sites in all
Eisai Co., Ltd.Eisai
NCT04565574 · 42 participants · Start Oct 16, 2020 · Primary completion Mar 31, 2021
Drug: E7090; Rabeprazole 20 mg and 1 more · For: Healthy Participants
Sites: Minatoku, Japan
Eisai Co., Ltd.Eisai
NCT02275910 · 40 participants · Start Oct 28, 2014 · Primary completion Sep 3, 2021
Drug: E7090 · For: Tumors
Sites: Nagoya, Japan; Kashiwa, Japan; Matsuyama, Japan · 18 sites in all
Eisai Co., Ltd.Eisai
NCT04271488 · 18 participants (planned) · Start Feb 27, 2020 · Primary completion Aug 31, 2027
Drug: Tasurgratinib; Tasurgratinib · For: Hepatic Impairment
Sites: Hakata, Japan; Kurume, Japan; Yuhu, Japan · 8 sites in all
- A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male ParticipantsCompleted
Eisai LimitedEisai
NCT04493255 · 8 participants · Start Sep 9, 2020 · Primary completion Oct 21, 2020
Drug: [14C]E7090 · For: Healthy Volunteers
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- FGFR1-driven brachyury promotes endothelial-like differentiation of glioblastoma stem cells via SOX2/ZEB1/YAP1 signaling pathways.
Hu Y, Mott BT, Yang W, et al. · Cell Signal 2026
- Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.
Shen L, Duan H, Kuwahara T, et al. · Jpn J Clin Oncol 2025
- Effect of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2- Breast Cancer Preclinical Models.
Kawano S, Fukushima S, Nishibata K, et al. · Cancers (Basel) 2025
- Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.
Morizane C, Ueno M, Ioka T, et al. · Cancer Sci 2025
- A sensitive assay for the determination of E7090, a novel selective inhibitor of fibroblast growth factor receptors, and its metabolite in human plasma by UPLC-MS/MS with at-column dilution.
Mano Y, Nitanai I, Hotta K · J Pharm Biomed Anal 2024
- A validated UPLC-MS/MS assay of E7090, a novel selective inhibitor of fibroblast growth factor receptors, in human plasma and urine.
Asakawa Y, Sano T, Hotta K, et al. · J Pharm Biomed Anal 2023
Also in development for Cholangiocarcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- certepetideCEND-1, LSTA1Phase 21 trial
Lisata Therapeutics, Inc. · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
- CGT4859Phase 21 trial
Cogent Biosciences, Inc. · Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult
- gavo-celPhase 21 trial
TCR2 Therapeutics · Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura
- GNS561Phase 21 trial
Genfit · Cholangiocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.